Arch Therapeutics Inc. (OTCQB: ARTH) Starts Presentation at The LD 500
Arch Therapeutics Inc. (OTCQB: ARTH) is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's development stage product candidates include AC5 Advanced Wound System, AC5 Topical Hemostat, AC5-G and AC5 Surgical Hemostat. The U.S. Food and Drug Administration (FDA) has provided clearance to market AC5(R) Topical Gel to be used in the management of partial and full-thickness wounds, such as pressure sores,…







